Meta-analysis Of The Safety Of Sacubitril Valsartan Sodium In The Treatment Of Essential Hypertension

Objective:To systematically evaluate the safety difference between Sacubitril Valsartan Sodium and other controllable drugs in the treatment of essential hypertension.Methods:The database was searched from“The Cochrane Labrary”,“PubMed”,“Web of Sciense”,“Chinese National Knowledge Infrastructure”,“Wanfang Database”and“Weipu Website”.The search time was from database construction to October 2018 and search scope included Chinese and English literature related to Sacubitril Valsartan Sodium.According to the developed experimental design,the literature was selected and the literature scores of the included studies were scored,the Jadad score table was used for scoring.The safety-related data in the literature was collected.A data table was established,and the meta-analysis method was selected according to the type of the data.(OR)and its 95%CI indicate the effect size,and the heterogeneity analysis of the data content,using I2 and P values as the basis.If the I~2?50%,the result of P?0.1 would remind that there is no heterogeneity between them,or the heterogeneity degree is low.According to the requirements of Cochrane's hand,the meta-analysis is performed using the fixed effect model.Similarly,if I~2>50%,P<0.1 suggests that there is a difference between the results included.According to the requirements of the Cochrane manual,use the random effects model to perform meta-analysis,further analyze the source of heterogeneity,such as the existence of statistical heterogeneity,select the corresponding statistical model analysis,otherwise select descriptive analysis.Meta analysis was performed using RevMan 5.3 software(provided by Cochrane).Results:A total of 5 literatures were included in the study.All of them were randomized double-blind controlled clinical trials.The quality of the literature showed that the quality of the included studies was good.Meta-analysis of the literature safety data showed that the overall adverse event rate was Sacubitril Valsartan Sodium 200mg.There was no significant difference in the overall adverse event rate between the three doses of 400mg and 100mg,and Sacubitril Valsartan Sodium did not show more adverse events when the dose was increased.This result indicates that the safety was better at clinical dose(Sacubitril Valsartan Sodium of200mg).Compared with the controllable group,there was no significant difference in the incidence of SAE and the incidence of AE withdrawal test.It can be seen that the patient has good tolerance to Sacubitril Valsartan Sodium 200mg.From the specific adverse events,the main adverse events of 200mg Sacubitril Valsartan Sodium are nasopharyngitis and dizziness.Upper respiratory tract infections have an odds ratio of1.22,1.02,and 1.03,respectively.These adverse events may have an effect on the patients'compliance with medication.But from the results of the meta-analysis,these adverse events were different from ARB drugs.Not significant difference suggested that this may be related to the mechanism of action of ARB drugs.Because there were less than 10 studies included,no literature bias evaluation was performed.Conclusions:A meta-analysis Sacubitril Valsartan Sodium according to five literatures were performed in the study.The result showed that Sacubitril Valsartan Sodium displayed similar the“incidence of overall adverse events”,the“SAE”and the“common adverse events”,in comparison with placebo,ARB,and drug combination,in the treatment of essential hypertension.Based on the research,all the groups showed good tolerance and the clinical antihypertensive therapy was safe.